Nucleic Acid Therapeutics for Rare Diseases (NAT-RD) @ Biobizkaia Health Research Institute
Posters
RNANet-Spain: The Spanish National Network for Personalised RNA Therapies. N1C Annual Meeting. 2025.
RNANet-Spain: The Spanish National Network for Personalised RNA Therapies. Oligonucleotide Therapeutics Society Meeting. Budapest, Hungary, 2025.
Arechavala-Gomeza, Larran, Revert Barberà, Corral-Juan, Borras, Pérez-Gómez, Orduña, Laresgoiti, López-Castel, Nogales-Gadea. Oligonucleotide Therapeutics Society Meeting. Budapest, Hungary, 2025.
Osegui-Barcenilla, Sendino, Martín-González, González-Moro, Benito-Agustino, Torres-Conde, López-Martínez, Jiménez-Mallebrera, López-Márquez, V. Arechavala-Gomeza. International Congress of the World Muscle Society. Vienna, Austria, 2025. Neuromuscular Disorders.
Osegui-Barcenilla, Sendino, Martín-González, González-Moro, Benito-Agustino, Torres-Conde, López-Martínez, Jiménez-Mallebrera, López-Márquez, V. Arechavala-Gomeza. International Congress of the World Muscle Society. Vienna, Austria, 2025. Neuromuscular Disorders.
Osegui-Barcenilla, Sendino, Martín-González, González-Moro, Benito-Agustino, Torres-Conde, López-Martínez, Jiménez-Mallebrera, López-Márquez, V. Arechavala-Gomeza. Scientific and Family Conference. Philadelphia, USA, 2025.
Sendino, Martin-González, Osegui, López-Márquez, González-Moro Benito-Agustino, López-Martínez, Jimenez-Mallebrera, V. Arechavala-Gomeza. International Congress of the World Muscle Society. Prague, Czech Republic, 2024. Neuromuscular Disorders.
López Martínez, Sendino Torres Conde, Al-Ani, Martín-gonzález, Nuñez-Manchón, Nogales Gadea, V. Arechavala Gomeza. International Congress of the World Muscle Society. Prague, Czech Republic, 2024. Neuromuscular Disorders.
López-Martínez; Soblechero-Martín; Catalli, Jauregi-Barrutia, Nogales-Gadea; Kapetanovic-Garcia; Arechavala-Gomeza. International Congress of the World Muscle Society. Halifax, Canada (online), 2022. Neuromuscular Disorders 32, S132-S133.
Andrea López-Martínez1, Patricia Soblechero-Martín, Virginia Arechavala-Gomeza. ESHG 2022 European Human Genetics. Vienna, Austria.
López-Martínez; Soblechero-Martín; Catalli Nogales-Gadea; Kapetanovic-Garcia; V. Arechavala-Gomeza. International Congress Neuromuscular Diseases (ICNMD 22). Brussels, Belgium, 2022. Journal of Neuromuscular Diseases, vol. 9, no. s1, pp. S1-S331.
A López-Martínez, P Soblechero-Martín, C Catalli, A Jauregui-Barrutia, S Kapetanovic-Garcia, V Arechavala-Gomeza. 13th International Myotonic Dystrophy Consortium Meeting. Japan (online), 2022.
P. Soblechero-Martín, A. López-Martinez, V. Arechavala-Gomeza. International Congress of the World Muscle Society. Online, 2021. Neuromuscular Disorders.
P. Soblechero-Martín, A. López-Martinez, V. Arechavala-Gomeza. International Congress Neuromuscular Diseases (ICNMD 21). Valencia (online), 2021. Journal of Neuromuscular Diseases, vol. 8, no. s1.
Virginia Arechavala-Gomeza on behalf of DARTER COST Action “Networking to improve the Delivery of Antisense RNA therapeutics” ESGCT Meeting Barcelona, Spain. Human Gene Therapy.
P. Soblechero-Martin, E. Albiasu-Arteta, J. Poyatos-García, G. González-Iglesias, A. Anton-Martínez, A. López-Martínez, V. Arechavala-Gomeza “A CRISPR/Cas9 edition protocol for human myoblasts to generate disease models” ESGCT Meeting Barcelona, Spain. Human Gene Therapy.
Virginia Arechavala-Gomeza on behalf of DARTER COST Action “Networking to improve the Delivery of Antisense RNA therapeutics” Oligonucleotide Therapeutics Society. Munich, October 2019.
J. Poyatos-García, P. Soblechero-Martín, E. Albiasu-Arteta, V. Arechavala-Gomeza, R. Vázquez-Manrique, N. Muelas, P. Martí, C. Gomis, J. Vilchez “Dystrophinopathic subjects with a specific mega-deletion of exons 45-55 in the DMD gene, as a template for CRISPR/Cas9 therapy in Duchenne muscular dystrophy”. International Congress of the World Muscle Society 2019, Copenhagen, Denmark. (Neuromuscular Disorders, Vol. 29, S152).
P. Soblechero-Martin, E. Albiasu-Arteta, J. Poyatos-García, G. González-Iglesias, A. Anton-Martínez, A. López-Martínez, V. Arechavala-Gomeza. “Overcoming barriers to establish a CRISPR/Cas9 edition protocol for human myoblasts” International Congress of the World Muscle Society 2019, Copenhagen, Denmark. (Neuromuscular Disorders, Vol. 29, S152)
P. Soblechero-Martín, E. Albiasu-Arteta, G. González-Iglesias, I. Larrañaga-Aiestaran, V. Arechavala-Gomeza “Quantifying muscle proteins in cell culture to screen potential treatments for neuromuscular disorders”. International Congress on Myology. Bordeux, France, March 2019.
E Ruiz-Del-Yerro, P Soblechero-Martin, I Larrañaga, E Albiasu-Arteta, V Arechavala-Gomeza “Myoblots for the evaluation of new treatments in neuromuscular disorders”. Neurogune, Vitoria, Spain, September 2018.
P Soblechero-Martin, I García-Jiménez, E Ruiz-Del-Yerro, E Albiasu-Arteta, V Arechavala-Gomeza “CRISPR/Cas gene editing in Duchenne muscular dystrophy cultures to test new treatments for the disease”. Neurogune, Vitoria, Spain, September 2018.
E Ruiz-Del-Yerro, P Soblechero-Martin, I Larrañaga, E Albiasu-Arteta, V Arechavala-Gomeza “Myoblots for the evaluation of new treatments in neuromuscular disorders”. International Congress on Neuromuscular Disorders. Vienna, Austria. July 2018. (Journal of Neuromuscular Disorders, vol. 5, no. s1, pp. S1-S408, 2018.
P Soblechero-Martin, I García-Jiménez, E Ruiz-Del-Yerro, E Albiasu-Arteta, V Arechavala-Gomeza. “CRISPR/Cas gene editing in Duchenne muscular dystrophy cultures to test new treatments for the disease”. International Congress on Neuromuscular Disorders. Vienna, Austria, July 2018. (Journal of Neuromuscular Disorders, vol. 5, no. s1, pp. S1-S408.
P. Soblechero-Martín, E. Ruiz-Del-Yerro, I. García-Jimenez, V. Arechavala-Gomeza. “Terapias Avanzadas para Enfermedades Neuromusculares”. Science + ERA Career Day, Bilbao, Spain, Sept 2017.
Ruiz-Del-Yerro, I. García-Jimenez, V. Arechavala-Gomeza “Myo-cytoblots: quantification of dystrophin by in-cell western assay for a streamlined development of DMD treatments”. Action Duchenne International conference. London, United Kingdom. November 2016. AWARD WINNING POSTER.
I. García-Jimenez, E. Ruiz-Del-Yerro, V. Arechavala-Gomeza “Selection of reference genes for normalisation of dystrophin mRNA RT-qPCR data”. Action Duchenne International conference. London, United Kingdom, November 2016.
Ruiz-Del-Yerro, I. García-Jimenez, V. Arechavala-Gomeza “Myo-cytoblots: quantification of dystrophin by in-cell western assay for a streamlined development of DMD treatments” 21st International Congress of the World Muscle Society 2016, Granada, Spain. (Neuromuscular Disorders, Vol. 26, S159 )
I. García-Jimenez, E. Ruiz-Del-Yerro, V. Arechavala-Gomeza “Selection of reference genes for normalisation of dystrophin mRNA RT-qPCR data”. 21st International Congress of the World Muscle Society 2016, Granada, Spain. (Neuromuscular Disorders, Vol. 26, S159–S160)
Ruiz-Del-Yerro, I. García-Jimenez, V. Arechavala-Gomeza “Myo-cytoblots: a method to quantify of dystrophin by in-cell western assay to accelerate preclinical assessment of DMD treatments” Neurogune June 2016, Bilbao, Spain.
Hiller, M.S. Falzarano, I. Garcia, Rudie Weij, V. Sardone, L. Popplewell, E. Ruiz-Del-Yerro, K. Anthony, R. Verheul, J Morgan, G. Dickson, F. Muntoni, A. Aartsma-Rus, A. Ferlini, V. Arechavala-Gomeza, et al. “Multicenter quantification of dystrophin exon 51 skipping” 11th Annual Meeting Oligonucleotide Therapeutics Society, October 2015, Leiden, Netherlands.
Ruiz-Del-Yerro, I. García-Jimenez, V. Arechavala-Gomeza. “Quantifying dystrophin in cell culture: a method to accelerate preclinical assessment of DMD treatments” 20th International Congress of the World Muscle Society 2015, Brighton, UK. Neuromuscular Disorders, (October 2015,Volume 25, Supplement 2, Page S254).
Ruiz-Del-Yerro, I. García-Jimenez, V. Arechavala-Gomeza. “Terapias avanzadas para enfermedades Neuromusculares” Science+ (ORGANISED BY CERU/SRUK) May 2015, Bilbao, Spain.
S. Torelli, K Anthony, V Arechavala-Gomeza, et al. “Towards a consensus on biochemical outcome measures for Duchenne muscular dystrophy clinical trials” UK Neuromuscular Translational Research Conference 2014, London, UK. Neuromuscular disorders (March 2014 Volume 24, Supplement 1, Page S11.
V Arechavala-Gomeza, C Godfrey, A Hibbert et al. “Optimising novel imaging methods to quantify low levels of dystrophin in Duchenne muscular dystrophy” UK Neuromuscular Translational Research Conference 2013, Oxford, UK.
K Anthony, V Arechavala-Gomeza et al. “Biochemical and Clinical Variability of Becker Muscular Dystrophy: Predicting Optimal Target Exons for Exon Skipping Therapy in Duchenne Muscular Dystrophy”. 17th International Congress of the World Muscle Society. Perth, Australia, 2012. Neuromuscular Disorders Vol. 22, Issue 9, Page 862.
L Popplewell, V Arechavala-Gomeza, et al (2012). The next DMD exon skipping trial: selection of AO target. 5th UK Neuromuscular Translational Research Conference. Newcastle, UK, March 2012. Neuromuscular Disorders Vol. 22 Supplement 1, Pages S9-S10.
K Anthony, S Cirak, S Torelli, G Tasca, L Feng, V Arechavala-Gomeza, et al. “Correlation of internally deleted dystrophin and dystrophin-associated protein expression with clinical severity in Becker muscular dystrophy”. 5th UK Neuromuscular Translational Research Conference. Newcastle, UK, March 2012. Neuromuscular Disorders Vol. 22 Supplement 1, Page S7.
S Cirak, V Arechavala-Gomeza, et al. Exon skipping and dystrophin restoration in Duchenne Muscular Dystrophy patients after systemic phosphorodiamidate morpholino oligomer treatment. 9th European Paediatric Neurology Society Congress. Dubrovnik, Croatia, May 2011.
S Cirak, V Arechavala-Gomeza et al. Exon skipping and dystrophin restoration in Duchenne Muscular Dystrophy patients after systemic phosphorodiamidate morpholino oligomer treatment. 4rd UK Neuromuscular Translational Research Conference. London, UK April 2011. PUBLICATION: Neuromuscular Disorders March 2011 (Vol. 21Supplement 1, Pages S7-S8).
S. Cirak; L. Feng; S. Torelli; V. Arechavala-Gomeza; et al Induction of dystrophin in DMD patients by antisense oligonucleotide AVI-4658 restores the dystrophin glycoprotein complex. 15th International Congress of the World Muscle Society. Kumamoto, Japan, October 2010. Neuromuscular Disorders(Vol 20, Page 643).
S Cirak, Feng, L,V Arechavala-Gomeza et al. “Induction of dystrophin in DMD patients by antisense oligonucleotide AVI-4658 restores the dystrophin glycoprotein complex”. 3rd UK Neuromuscular Translational Research Conference. Oxford, UK March 2010. PUBLICATION: Neuromuscular Disorders March 2010 (Vol. 20 Supplement 6).
Malerba, P. Sharp, IR Graham, V Arechavala-Gomeza, K Foster, JE Morgan, F Muntoni, D Wells, G Dickson. “Chronic long term administration of phosphorodiamidate morpholino oligomer profoundly ameliorates activity, muscle strength and phenotype in dystrophic mdx mice”. 3rd UK Neuromuscular Translational Research Conference. Oxford, UK March 2010. PUBLICATION: Neuromuscular Disorders March 2010 (Vol. 20 Supplement S12).
Jihee Kim, V. Arechavala-Gomeza, Muntoni F. The characterisation of out of frame duplications in DMD patients. 3rd UK Neuromuscular Translational Research Conference. Oxford, United Kingdom March 2010. Neuromuscular Disorders 20 (pp. S5).
Malerba, P. Sharp, IR Graham, V Arechavala-Gomeza, K Foster, JE Morgan, F Muntoni, D Wells, G Dickson. “Clinically Applicable Dosing Regimens of Phosphorodiamidate Morpholino Oligomer Profoundly Improve Behaviour, Activity, and Dystrophic phenotype in mdx mice”. 7th Annual Conference of the British Society for Gene Therapy. Egham, England, March 2010. Human Gene Therapy, Mary Ann Liebert Inc, 508–508.
V. Arechavala-Gomeza, on behalf of the MDEX consortium. Developing and delivering antisense strategies for Duchenne muscular dystrophy. TREAT-NMD International Conference. Brussels, Belgium, December 2009.
Arechavala-Gomeza, et al. Measuring restored dystrophin in treated muscle: An immunohistological intensity measurement method. 14th International Congress of the World Muscle Society. Geneva, Switzerland, September 2009. Neuromuscular Disorders (Vol. 19, Issue 8, Page 615).
V Arechavala-Gomeza, et al. Measuring restored dystrophin in treated muscle: An immunohistological intensity measurement method. 2nd UK Neuromuscular Translational Research Conference. Newcastle, United Kingdom, May 2009.
Kinali, V. Arechavala-Gomeza, et al. Establishing the parameters for clinical trials of antisense oligonucleotide therapy in Duchenne muscular dystrophy, 13th International Congress of the World Muscle Society. Newcastle, United Kingdom, October 2008. Neuromuscular Disorders (Vol. 18, Issue 9, Page 773).
C Adkin, V. Arechavala-Gomeza, et al. “A model of human muscle regeneration in vivo to test potential therapies for DMD” 13th International Congress of the World Muscle Society. Newcastle, United Kingdom, October 2008.Neuromuscular Disorders (Vol. 18, Issue 9, Page 759).
Kinali, V. Arechavala-Gomeza, et al. Establishing the parameters for clinical trials of antisense oligonucleotide therapy in Duchenne muscular dystrophy. British Paediatric Neurology Association conference. Leeds, UK, 2008. Developmental Medicine & Child Neurology 50, 6-32.
Arechavala-Gomeza, Maria Kinali et al. Do revertants increase with age in Duchenne muscular dystrophy boys? 12th International Congress of the World Muscle Society. Sicily, Italy, October 2007. Neuromuscular Disorders (Vol. 17, Issue 9, Page 842).
V. Arechavala-Gomeza, Bushby, K., Dickson, G., Graham, I., Kinali, M., Liu, K., Yin, H. A phase I/II clinical trial in Duchenne muscular dystrophy using IM and IV delivered antisense oligonucleotides: The MDEX consortium 11th International Congress of the World Muscle Society. Brugges, Belgium, October 2006. Neuromuscular Disorders (Vol. 17, Issue 9, Page 842).
V. Arechavala-Gomeza, et al. SOD 1 mutant proteins misfolding and aggregation. Implications of dimerization and metal deficiency. 2nd Meeting of the European ALS/MND Consortium. Nice, France, April 2004.
V. Arechavala-Gomeza, et al. SOD1 mutant proteins misfolding and aggregation: implications of dimerization 14th International Symposium on ALS/MND. Milan, Italy, October 2003. ALS and other motor neuron disorders 2003 4 (Suppl 1), 79–96.
13th International Symposium on ALS/MND. Melbourne, Australia, 2002.
12th International Symposium on ALS/MND. Oakland, USA, 2001.
